Chances of left ventricular ejection fraction almost disappeared when patient took the ACE-inhibitor lisinopril during treatment with trastuzumab/anthracycline, according to research presented at ASCO.
Denise Myshko
Advertisement
Articles by Denise Myshko
Immune-related AEs can occur one to two years after treatment, are more common in combination treatments, and can be difficult to manage.
Three commercial plans now cover the corticosteroid Eysuvis.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
New hypertension drugs show no advantage over older generics
2
Inaccurate data in provider directories is costing health plans. Why a national provider diectory and data science are the fix
3
Noninvasive imaging of basal cell carcinoma: Examining the choices
4
Physicians may be the key for affordable healthcare
5